Suppr超能文献

重新评估脑死亡供体肝移植的生存获益:回顾性队列研究。

Reassessing the survival benefit of deceased donor liver transplantation: retrospective cohort study.

机构信息

Department of Surgery.

Department of Medicine, University of Colorado Anschutz Medical Campus.

出版信息

Int J Surg. 2023 Sep 1;109(9):2714-2720. doi: 10.1097/JS9.0000000000000498.

Abstract

INTRODUCTION

Currently in the United States, deceased donor liver transplant (DDLT) allocation priority is based on the model for end-stage liver disease including sodium (MELD-Na) score. The United Network for organ sharing's 'Share-15' policy states that candidates with MELD-Na scores of 15 or greater have priority to receive local organ offers compared to candidates with lower MELD-Na scores. Since the inception of this policy, major changes in the primary etiologies of end-stage liver disease have occurred and previous assumptions need to be recalibrated.

METHODS

The authors retrospectively analyzed the Scientific Registry of Transplant Recipients database between 2012 and 2021 to determine life years saved by DDLT at each interval of MELD-Na score and the time-to-equal risk and time-to-equal survival versus remaining on the waitlist. The authors stratified our analysis by MELD exception points, primary disease etiology, and MELD score.

RESULTS

On aggregate, compared to remaining on the waitlist, a significant 1-year survival advantage of DDLT at MELD-Na scores as low as 12 was found. The median life years saved at this score after a liver transplant was estimated to be greater than 9 years. While the total life years saved were comparable across all MELD-Na scores, the time-to-equal risk and time-to-equal survival decreased exponentially as MELD-Na scores increased.

CONCLUSION

Herein, the authors challenge the perception as to the timing of DDLT and when that benefit occurs. The national liver allocation policy is transitioning to a continuous distribution framework and these data will be instrumental to defining the attributes of the continuos allocation score.

摘要

简介

目前,在美国,已故供体肝移植(DDLT)的分配优先级基于终末期肝病模型,包括钠(MELD-Na)评分。美国器官共享网络的“Share-15”政策规定,MELD-Na 评分达到 15 或更高的患者与评分较低的患者相比,优先接受当地器官的供应。自该政策实施以来,终末期肝病的主要病因发生了重大变化,需要重新校准先前的假设。

方法

作者回顾性分析了 2012 年至 2021 年期间的移植受者科学登记处数据库,以确定在每个 MELD-Na 评分间隔内,通过 DDLT 挽救的生命年数,以及达到等待名单上同等风险和生存时间的时间。作者根据 MELD 例外点、主要疾病病因和 MELD 评分对分析进行分层。

结果

总体而言,与继续等待相比,作者发现 MELD-Na 评分低至 12 的患者进行 DDLT 具有显著的 1 年生存率优势。估计在这种评分下进行肝移植后,中位可挽救的生命年限超过 9 年。虽然所有 MELD-Na 评分的总生命年挽救数相当,但达到同等风险和生存时间的时间随着 MELD-Na 评分的增加而呈指数级下降。

结论

作者在此质疑进行 DDLT 的时机以及何时会产生这种益处的看法。国家肝脏分配政策正在向连续分配框架转变,这些数据对于定义连续分配评分的属性将是至关重要的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71ed/10498891/240c75af01bc/js9-109-2714-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验